The US Food and Drug Administration has approved Takeda Pharmaceuticals U.S.A., Inc.’s Dexilant SoluTab delayed-release orally disintegrating tablets, a new formulation of dexlansoprazole that can be taken by allowing the tablet to melt in the patient's mouth. Dexilant SoluTab is a proton pump inhibitor (PPI) indicated for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) and the maintenance of healed erosive esophagitis (EE) and relief of heartburn in adults 18 years and older. Dexilant SoluTab is a PPI with dual delayed-release (DDR) technology that is designed to provide two separate releases of medication.

In addition to Dexilant SoluTab, Dexilant is also available as a capsule. The capsule is indicated for heartburn associated with symptomatic non-erosive gastroesophageal reflux disease, the healing of erosive esophagitis (EE) and the maintenance of healed EE in adults. Since being approved by the FDA, Dexilant capsules have been available for nearly seven years with over 25 million prescriptions filled.

Source: Takeda Pharmaceutical